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Summary 
The generation of knockout mice with targeted gene disruption has provided a valuable tool 
for studying the immune response. Here we describe the use of CD4 and CD8 knockout mice 
to examine  the  role of CD4 + and  CD8 + cells  in initiating  allotransplantation  rejection.  Pre- 
treatment with a brief course of depletive anti-CD4 monoclonal antibody therapy allowed per- 
manent survival of heart,  but not skin,  allografts transplanted across a major histocompatlbility 
barrier.  However, skin as well as heart grafts were permanently accepted in the CD4 knockout 
mice.  Transfer of CD4 + cells into CD4 knockout recipient mice 1 d before skin engraftment 
reconstituted rejection,  demonstrating that CD4 + cells are necessary for initiating rejection of 
allogeneic  transplants.  Major  histocompatibility  complex  disparate  heart  and  skin  allografts 
transplanted into CD8 knockout recipients were rejected within  10 d. This study demonstrates 
that CD4 + but not CD8 + T  cells are absolutely required to initiate allograft rejection. 
T 
he relative importance of the CD4 + and CD8 + T  cell 
subpopulations  in  mediating  transplant  rejection  re- 
mains  controversial.  In certain  settings,  CD8 +  cells  alone 
seem  to  be  able  to  initiate  allorejection  (1).  However, 
CD4 +  T  cells  have  been  shown  to  play  a  central  role  in 
transplantation  rejection  (2-6). Whether CD4 + T  cells  are 
absolutely  required  to  initiate  allograft  rejection  has  been 
the  subject  of a  dispute.  Naive  CD4 +  and/or  CD8 +  sub- 
populations  have  been  adoptively  transferred  into  immu- 
noincompetent  nude  mice  to  assess their  abihty  to  reject 
skin  allografts  (7).  This  study  indicated  that  skin  allograft 
rejection  was mediated by collaborations  in vivo between 
T  inducer and effector cells,  and that two interacting T  cell 
subsets can express different phenotypes as well as different 
antigen speclficities.  These experiments  estabhshed the cri- 
terion  that  rejection  requires  two  T  cell  subpopulations: 
one providing help,  the  other cytotoxic effector funcnon. 
In certain  mouse  strains  (e.g.,  B6  and  B10),  MHC  class 
I-reacnve CD8 + cells can be activated in vitro independent 
of MHC  class  II-reactlve  CD4 +  cells  (7-9).  CD8 +  cells 
have also been shown to be the only subset effective in re- 
storing  rejection  of MHC  class  I  incompatible  grafts  (8, 
10),  and skm grafts from strains with isolated MHC  class  I 
mutanons (7, 9). However, these investigators eliminated T 
cell subsets by treatment with specific mAbs in vivo to de- 
plete either CD4 + or CD8 + T  cells,  and it was possible that 
reconstituted  nude  mice  contained  T  cells  derived  either 
from the nude host animal or, more likely, from contami- 
nating T  cells in the reconstituting T  cell population.  It has 
recently  been  shown  that,  despite  marked  depletion  of 
CD8 + T  cells after treatment with anti-CD8 mAbs in vivo, 
a unique subpopulation of CD8 + cells  remained which re- 
jected  MHC  class  I  disparate  skin  grafts and  generated  al- 
lospecific  CTL  responses  (11).  Contamination  of "puri- 
fied" T  cell subpopulations has also been shown to occur in 
an adoptive transfer study using mAbs to negatively select 
purified  T  cell  subpopulations  to  determine  the  relative 
contributions of CD4 + and CD8 + cells from diabetic mice 
into NOD-scid mice, where purified donor CD4 + popula- 
tions revealed <2.5% contaminating CD8 + T  cells  (12). 
Targeting  the  CD4  or  CD8  molecule  with  mAb  to 
eliminate  or inactivate  CD4 +  or CD8 + T  cells has been a 
promising strategy for the induction of transplantation  tol- 
erance.  Depleting regimens  of anti-CD4  mAbs have been 
shown to induce long-term survival (tolerance)  of pancre- 
atic islet  (13)  and vasculanzed heart allografts  (14-17),  but 
only delay skin graft (18,  19)  survival m  rodents.  A  variety 
of mechanisms for anti-CD4-induced tolerance have been 
suggested (14, 20--23). 
Anti-CD8  mAb  therapy,  on  the  other  hand,  has  had 
variable  results.  Although  nondepleting  anti-CD8  therapy 
has been shown to induce permanent survival of vascular- 
ized heart allografts in mice (16, 24), mace treated with de- 
pleting  anti-CD8  rejected  their  allografts  (16).  Anti-CD8 
therapy also did not prolong heart or islet allograft survival 
in  rats  (25,  26),  nor  did  it  prolong  skin  graft  survival  an 
mice  (19,  27).  However,  antl-CD8  combined  with  anti- 
CD4 treatment has been shown to prolong Islet (28), bone 
marrow (19, 27), skin (27), and vascularazed heart (16) graft 
survival. 
Although  using  anti-CD4  or  anti-CD8  mAbs  is  one 
strategy for studying the induction of tolerance,  the inter- 
action between the mAb and the target molecule could in- 
duce  multiple  immunological phenomena.  Not  all  CD4 + 
2013  j. Exp. Med. © The Rockefeller University  Press • 0022-1007/96/{)8/2013/06 $2.00 
Volume 184  August 1996  2013-2018 or CD8 + cells are depleted in studies using depleting anti- 
CD4 or anti-CD8 therapy. Thus, the use of depleting anti- 
CD4  or anti-CD8  mAbs does  not  exclude  the  possibility 
that signals generated as a result of the interaction between 
the antibody and the target molecule on residual CD4 + or 
CD8 ÷  cells are  involved in  unresponsiveness  (29).  Addi- 
tionally, nondepleting anti-CD4  or  anti-CD8  mAbs  may 
potentially affect CD4 ÷ or CD8 ÷ T  cell function by direct 
blockade, by transmitting a negative signal, or by interfer- 
ing with normal signal transduction mechanisms. 
To avoid inherent questions regarding the efficacy versus 
mechanisms  of anti-CD4  or anti-CD8  induced tolerance, 
we  studied allotransplantation in CD4  and  CD8  knockout 
mice that were generated using homologous recombination 
in  pluripotent  embryonic  stem  cells  (30,31).  Although  it 
has  previously been  shown  that  skin  allografts from  mice 
lacking either class I  ([32-microglobulin or TAP1  and  [32- 
microglobulin),  class  II  (A[33)  or both  class  I  and  class II 
(132-microglobulin  and  A[33)  are  rejected  (32,  33),  these 
mice  contain  a  small  number  of  CD4 +  and/or  CD8 + 
T  cells. We expanded upon these studies by directly testing 
the  hypothesis  that  the  complete  absence  of CD4 ÷  (or 
CD8 + cells) would block the initiation ofallorejection and 
consequently  allow  the  mdefinite  survival  of  allografts. 
Here we report that rejection can occur in the absence of 
CD8 + cells, and that CD4 + cells are required for allorejec- 
tion. 
Materials  and  Methods 
Mice.  Inbred male  C57BL/6  (H-2b,  B6),  BALB/c  (H-2d), 
and A/J (H-2a) mice were purchased from The Jackson Labora- 
tory (Bar Harbor, ME); BALB/c CD4 knockout and BALB/c or 
PL/J(H2u) CD8 knockout mice (homologous for disrupted CD4 
or CD8 gene as previously described [30, 31]) were the generous 
gaft of Dr. Tak Mak (University of Toronto). The animals were 
housed and bred m pathogen-free con&tlons in the Stanford De- 
partment of Laboratory Animal Medicine (DLAM) according to 
the National Institutes of Health guidelines. 
mAb and Immunosuppression.  The mAb used in these studies, 
GK1.5 (CD4), is a rat immunoglobuhn (IgG2b) directed against 
mouse  L3T4  (34).  GK1.5  was  produced  from  ascites  in  nude 
lance primed with pnstane (Sigma Chemical Co., St. Louis, MO) 
followed  by  intraperitoneal  inoculation  of  GK1.5  hybridoma 
cells.  The antibody was purified via passage  over an affinity-gel 
protein A column. Antibody content was quantified by an optical 
density spectrometer (DU 640;  Beckman Instruments, Inc., Ful- 
lerton, CA) and quahtated by FACS  ® analysis and depletion stud- 
ies in vivo. The supernatant was passed through a 0.22-1*m  filter 
(Mlllipore Corp., Bedtbrd, MA) before being stored at -20°C. 5 
mg/kg ofannbody was administered at -3,  -2, -l,  and 0 d rel- 
ative to allograft transplantation. 
Heterotoptc Heart Transplantation,  Vascularized  heart grafts were 
transplanted using standard microsurgical techniques (35). Briefly, 
the harvested donor heart was placed in 4°C  saline until trans- 
plantation. The mouse was anesthetized by intraperitoneal injec- 
tion of Nembutal (50  mg/kg).  The donor aorta was sutured to 
the recipient aorta and the donor pulmonary artery to the recipi- 
ent inferior vena cava end to side using 10-0 suture. Transplant 
Table  1.  Anti-CD4 mAb (GK1.5) Allows Heart but not Skin 
Allograft Survival 
GK1.5  Allograft  Survival  MST +  SEM 
d 
+  Heart  60, 90, >100  ×  6  93.8 +  5.0* 
-  Heart  6, 7 ×  3, 8, 9  7.3 -+ 0.4 
+  Skin  8,  10, 11, 11, 11  10.2  -+ 0.6 
-  Skin  7, 8 ×  5  7.8 -+ 0.2 
Pretreatment  with a bnef course of GK1.5 allowed long-term survival 
ofA/J (H-2a) heart, but not sk, n allografts in C57BL/6  (H-2b, B6) re- 
clpmnts. 5 mg/kg of antibody GKI.5 was adrmmstered at -3, -2, -  1, 
and 0 d relative to allograft transplantation. 
*P <0.002; Mann-Whitney U test. 
function was evaluated by daily abdommal palpation. Cessation of 
palpable heartbeat was used to deterrmne the end point of rejec- 
tion. 
Skin Grafts.  Skin allografts taken from donor chest skin were 
grafted onto the flank of the recipients with a running 6-0 suture 
using the uncovered skin graft technique (36). Using this method, 
the skin graft was visible from the day of engraftment unnl rejec- 
tion was complete, and mice were not burdened by circumferen- 
tial body dressings.  Skin graft changes of shrinkage and black col- 
oration were defined as the time of rejection. 
MINIMACS Purification of CD4  + Cells.  Single cell suspensions 
of freshly isolated spleen and LN cells from naive BALB/c mice 
were counted and incubated with antl-CD4 magsletlc microbeads 
(Mdtenyi Biotec, Auburn,  CA) for 20 min on ice, washed, and 
purified by passage through magnetic flow columns. The eluent 
gave a population of 90% CD4 + cells by FACS  ® analysis (data not 
shown).  5  ×  107  CD4 + cells were then  inoculated intraperito- 
neally into each CD4 knockout mouse. 
Results  and  Discussion 
Skin  but  not  Heart  Allografts  Are  Rejected  in  anti-CD4 
mAb-Treated Mice.  Mice treated with anti-CD4 mAb ac- 
cepted heart but not skin allografts (Table 1). B6 mice that 
received a brief course ofanti-CD4 showed long-term sur- 
vival of A/J heart allografts (mean survival time [MST], 94 d). 
Skin allograft survival was not prolonged in the anti-CD4 
treated recipients compared with untreated controls (MST, 
10  and  8  d,  respectively). Other  investigators have  previ- 
ously shown that heart but not skin allografts were perma- 
nently accepted in mice treated with a short course of anti- 
CD4 therapy (16,  17,  19). 
Why are skin allografts rejected in the anti-CD4-treated 
mice? Generally, skin allografts induce stronger allospecific 
cellular immunity than heart allografts (1). It has been dem- 
onstrated in the anti-CD4-treated mice that "memory"  T 
cells persist despite depletion of peripheral CD4 + cells (23, 
37).  These  residual CD4 + T  cells (resistant memory  cells) 
may mediate the induction of graft rejection in response to 
highly immunogemc antigens present in skin grafts. Differ- 
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Allografis Indefinitely 
Strain 
combination  Allograft  Survival  MST +  SEM 
d 
B6 to CD4 KO BALB/c  Heart  >100 ×  8  100.0  +- 0.0" 
B6 to BALB/c  Heart  7, 8, 8, 9, 10  8.4 +  0.5 
B6 to CD4 KO BALB/c  Skin  >100 X 8  100.0  +  0.0" 
B6 to BALB/c  Skin  8, 8, 9, 10, 10  9.0 4- 0.4 
BALB/c CD4 knockout (KO) reclpmnts permanently accept C57BL/6 
(H-2b, B6) heart and skin allografts. 
*P <0.01, Mann-Whitney U test. 
ences in graft immunogenicity of skin grafts may be due to 
either the number of class  II passenger leukocytes (includ- 
ing Langerhans cells)  or the MHC  class I density in skin tis- 
sue.  Recognition  of minor or Qa differences  or skin-spe- 
cific  alloanngens  may  be  important  as  well  (38).  These 
differences  may initiate  a strong response  that  recruits  the 
small  number of residual  CD4 + cells  in  anti-CD4-treated 
recipients. 
Mice Lacking  CD4 + Cells but with Functional  CD8 + Cells 
Permanently Accept Heart and Skin Allografis.  C57BL/6  heart 
and  skin  allografts  were  permanently  accepted  in  the 
BALB/c CD4 knockout recipients (MST >100 d) (Table 2). 
Why  do  CD4  knockout  mice  not  reject  allotransplants? 
Mice lacking CD4 + cells through targeted gene disruption 
have previously been shown to have normal numbers of T 
and B  cells,  with peripheral  expansion  of the  CD8 + com- 
partment  (31).  The  CD4  knockout  mice  possess  an  ex- 
panded  subpopulation  of CD4-CD8-TCR-c~/]3 +  (double 
negative)  T  cells  in  the  thymus  and  periphery  that  is  not 
normally  found  in  significant  numbers  in  conventional 
mice  (31).  These mice have been shown to have intact  Ig 
isotype class switch from IgM to IgG in response to sheep 
erythrocytes  and  vesicular  stomatltis  virus  in vivo  (30).  It 
was  also  demonstrated  (using  depletive  regimens  of mAbs 
to various subpopnlations ofT cells in vivo) that the double 
negative  cells  were  responsible  for providing  help  m  the 
antibody response of CD4 knockout mice to vesicular sto- 
matitis virus infection (30).  These cells  were demonstrated 
to  be  class  II MHC-restricted  in  responses  against  the  T 
cell-dependent antigen KLH. CTLs were also shown to be 
generated  against  lymphocytic  choriomeningitis  and  vac- 
cinia  virus,  suggesting  that  CD8 +  cells  in  these  CD4 
knockout mice can mount an immune response in the ab- 
sence of CD4 + cells  (30). 
Double-negative T  cells  have been previously shown to 
have  suppressive  properties  (39).  It  is  possible  that  these 
CD4-CD8-TCP,.-c~/13 + T  cells are not only unable to ini- 
tiate  but  may  actively  suppress  a  response  against  the  al- 
lograft. The activity of these double-negative cells in CD4 
and  CD8  knockout  mice,  and  in  CD4-CD8-  double 
knockout  mice,  however,  has  been  variable.  In  CD4 
knockout  mice,  CD4-CD8-TCP,.-ot/~ +  cells  have  been 
shown to provide MHC  class  II-restricted help  in vitro as 
stated  above  (30).  Although  naive  CD8  knockout  mice 
have  normal  numbers  of  CD4-CD8-TCR.-ot/~ +  cells, 
double-negative cells are increased in CD8 knockout mice 
engrafted  with  an  MHC  class  I-disparate  skin  graft  (40). 
Double-negative cells  also significantly increase when thy- 
mocytes from these CD8 knockout mice are transferred to 
nude mice who receive and subsequently reject MHC  class 
II-deficient  skin  grafts.  CD4  depletion  with  anti-CD4 
mAbs m  CD8 knockout mice has no effect on rejection of 
MHC  class I-disparate skin allografts; thus residual nonde- 
pleted  CD4 +  or CD4-CD8-TCR-o~/~ +  cells  may play a 
role in this rejection. In CD4-CD8- knockout mice, CD4- 
CD8-TCR.-od[3 +  cells  have  been  shown  to  generate  al- 
loreactive cytolytic T  cells,  and recognize MHC  class I an- 
tigens  in  vitro  (41).  These  CD4-CD8-  double-knockout 
mice have been shown to reject skin grafts with major H-2 
histocompatibility disparities,  but accepted grafts with only 
minor  antigen  differences  (41).  To  address  the  possibility 
that CD4-CD8-TCP,.-od~ + cells in CD4 knockout recipi- 
ents serve as "suppressor cells,"  3.0-4.0  ×  107 spleen  cells 
from CD4 knockout mice bearing B6 hearts for over 100 d 
were  transferred  into  irradiated  (200  rads)  BALB/c  hosts 
along with a fresh donor-matched B6 heart allograft.  Tol- 
erance was not adoptively transferred to these naive recipi- 
ents; all B6 heart allografts were rejected within  18 d, sirm- 
lar to irradiated  controls (Table  3).  These data suggest that 
unresponsiveness  in the  CD4 knockout recipients  was not 
due  to the presence  of suppressor  CD4-CD8-TCR-e¢/13 + 
T  cells.  That double-negative cells  do not actively suppress 
allorejection  is  consistent  with  previous  results  in  both 
CD8  and  CD4-CD8-  knockout  mice  that  demonstrated 
that  double-negative  cells  tend  to  play  a  role  in  skin  al- 
lograft rejection rather than suppression. 
It is  therefore  most likely that  the  mechanism of unre- 
sponsiveness  to allografts in  the  CD4  knockout mice was 
due to the complete absence ofCD4 + T  ceils which would 
Table 3.  Adoptive  Transfer of Spleen Cells from  "Tolerant" 
CD4 Knockout Mice Does Not Prolong Allografi Suwival 
Strain  3-4 X  107  200 
combination  Splenocytes  rads  Survival  MST +  SEM 
d 
B6 to BALB/c  Tolerant  +  17, 18 ×  3  17.8 _  0.4 
CD4 KO 
B6 to BALB/c  None  +  16, 18 ×  3  17.5 _+ 0.8 
Transfer of 3-4  ×  107 spleen cells from CD4 KO mace beanng  al- 
lografted hearts for over 100 d into irradiated (200 rads) syngenelc hosts 
did not prevent allorejecnon of fresh B6 heart allografts m the nawe re- 
cipients of adopnve transfer. 
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Strain  Transferred  Mice with 
combinanon  cells  rejected grafts  Survival 
d 
B6 to CD4 KO  None  0/5  100  ×  8 
B6 to CD4 KO  CD4 + cells  5/7  13,  14, 15 ×  2, 
16, >3O X 2 
B6 to CD4 KO  CD8 KO cells  3/3  15, 16, 17 
CD4 KO BALB/c mice were given 5 ×  107 purified CD4 + cells  from 
conventional  naive BALB/c mice.  i  d after this adoptive transfer, the 
CD4 KO BALB/c mice received a B6 skin graft 
suggest  that  CD4 +  cells are  required  for  initiation  of al- 
lograft rejection.  To  address  this possibility, we  reconsti- 
tuted CD4  knockout mice with naive CD4 + cells just be- 
foreengraftment to see whether the addition of CD4 + cells 
would allow graft rejection.  1 d  after adoptive transfer of 
5  X  107  CD4 +  cells  from  conventional  naive  BALB/c 
mice  obtained  by  MINIMACS  purification,  the  CD4- 
reconstituted CD4  knockout BALB/c mice received a B6 
skin graft.  Control CD4  knockout mice received identical 
B6 skin grafts but did not receive CD4 cells before engraft- 
ment.  5  of 7  mice reconstituted with CD4 +  cells rejected 
their grafts  (Table 4).  This experiment was  then  modified 
to  avoid  the  possibility that  the  CD4 +  cells  isolated  by 
MINIMACS purification were "activated." CD4 knockout 
mice  were  reconstituted  with  cells  t?om  CD8  knockout 
mice  which  have  functionally  intact  CD4 +  cells  (31). 
Three  of  three  CD4  knockout  recipients  reconstituted 
with "CD4 cells" from CD8  knockout mice rejected their 
skin grafts (Table 4). 
CD8 Knockout Mice Reject Heart and Skin Allografts.  Al- 
though we have demonstrated that CD4 + cells are essential 
for allorejection, what is the role of the CD8 + cell? In cer- 
tain settings, CD8 + cells seem capable of initiating rejection 
in  concert  with  MHC  class  I  disparity  (1).  However,  as 
demonstrated  in  the  current  study,  CD8 +  cells alone,  al- 
though present in the CD4 knockout mice, could not ini- 
tiate allorejection. It is possible that the CD8 + cells which 
may normally play a role in graft rejection were unable to 
respond to alloantigens in the complete absence of CD4 + 
cell-mediated help.  This  question has been previously ad- 
dressed in CD8 knockout mice, which lack CD8 + cells but 
have  functional  CD4 +  cells  (31).  It  has  been  previously 
shown  that  CD8  knockout  mice  reject  MHC  class  I-or 
MHC  class II-disparate skin grafts without delay compared 
with  wild-type mice,  suggesting  that  CD8 +  cells are  not 
necessary for allorejection of either MHC  class I or class II 
grafts  (40).  More  recent  studies  have  demonstrated  that 
adoptive  transfer  of naive  or  sensitized  CD4 +  cells  from 
these  CD8  knockout  mice into  nude  mice  that  had been 
grafted with allogeneic skin from  mice deficient in MHC 
class I or class II (MHC  class II or MHC  class I allogeneic, 
respectively) reconstituted rejection, suggesting that CD4 + 
cells  were  sufficient  to  mediate  rejection  (42).  Although 
MHC  class I  skin allografts were  rejected, CD4 +  cells did 
not  display alloantigen-specific cytotoxic  activity,  though 
they proliferated in vitro in response to allogeneic targets. 
We also studied CD8 knockout mice as recipients of MHC 
disparate  allografts.  C57BL/6  skin  allografts  transplanted 
into BALB/c CD8  knockout mice were rejected in 8.7  + 
0.3  d  (compared  to  9.0  _+  0.4  d  for  BALB/c  controls), 
which  concurs  with  the  results  of  Dalloul  et  al.  (42). 
C57BL/6  heart  and  skin  allografts transplanted into  PL/J 
CD8  knockout  mice  were  rejected within  10  d  for  each 
graft separately (n =  14, data not shown). Collectivity these 
results  suggest  that  elimination  of cells bearing  the  CD8 
molecule  does  not  prevent  allorejection.  These  data  also 
demonstrate  that  CD4 +  cells can  initiate rejection.  Thus, 
our  results demonstrate  that  the  initiation of allorejection 
requires CD4 + and not CD8 + cells. 
In these experiments we have explored the role of CD4 
and  CD8  cells in  transplant  allorejection using  knockout 
mice as recipients of MHC  disparate allografts. The results 
demonstrate that heart and  skin allografts are permanently 
accepted in CD4  knockout mice, but are rejected in CD8 
knockout  mice.  Thus,  lack of CD4 +  cells allows perma- 
nent  survival of heart and  skin allografts in mice, whereas 
lack of CD8 +  cells does  not  prevent  allorejection. These 
results demonstrate that CD4 + cells, not CD8 + T  cells, are 
absolutely required  in  initiating allorejection.  Our  results 
also  demonstrate  that  allorejection does  not  require  both 
CD4 ÷ and CD8 + T  cell subpopulations. 
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